<code id='A3A10031CA'></code><style id='A3A10031CA'></style>

<acronym id='A3A10031CA'></acronym>

<center id='A3A10031CA'><center id='A3A10031CA'><tfoot id='A3A10031CA'></tfoot></center><abbr id='A3A10031CA'><dir id='A3A10031CA'><tfoot id='A3A10031CA'></tfoot><noframes id='A3A10031CA'>

<optgroup id='A3A10031CA'><strike id='A3A10031CA'><sup id='A3A10031CA'></sup></strike><code id='A3A10031CA'></code></optgroup>

<b id='A3A10031CA'><label id='A3A10031CA'><select id='A3A10031CA'><dt id='A3A10031CA'><span id='A3A10031CA'></span></dt></select></label></b><u id='A3A10031CA'></u>

~~<i id='A3A10031CA'><strike id='A3A10031CA'><tt id='A3A10031CA'><pre id='A3A10031CA'></pre></tt></strike></i>~~

Home» comprehensive» hotspot

hotspot

hotspot

author：knowledge 2025-09-30 06:41:25 Page View：81167

Alexis Borisy — Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

advertisement

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How generative AI ratchets up security threats for health systems
Next article： George Santos makes 1st court appearance after pleading not guilty to 13 counts

focus

How to save PrEP access — and even expand it

How to save PrEP access — and even expand it

UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

The debate over Covid

The debate over Covid

SyringeswiththePfizer-BioNTechCovid-19vaccineFREDERICJ.BROWN/AFPviaGettyImagesU.S.healthofficialswan

Medical records are filled with copy

Medical records are filled with copy

AdobeIrecentlytookcareofapatientwhosemedicalrecordsincludedmultiplenotesaboutherpastopen-heartsurger

Antibody drugs appear effective. Now can we make enough of them?

VincenzoRusso,aresearcheratRegeneron,workstoisolateviralDNAclonesofSARS-CoV-2.EricaYoonforSTATTheCov

read more